CO-OPTIV-SECURITY
While industries are being completely reinvented at an ever-accelerating pace, the overall approach to cybersecurity has not similarly evolved to address the new security challenges presented by rapid digital transformation. Talent shortages, expanding attack surfaces, and constant breaches are all symptoms of an unnecessarily complex and inefficiently constructed cybersecurity world. Optiv Security , a global cybersecurity integrator delivering end-to-end cybersecurity solutions, today announced it has implemented a new cybersecurity services approach, business and engagement model that transforms the way cybersecurity is consumed and applied. Optiv’s innovative approach is specifically designed to deliver to organizations integrated cybersecurity solutions that address the speed of business change, by providing new consumption and outcome-based consulting services and cybersecurity solutions that ultimately achieve higher performance and reduced overall operational costs.
Specifically, the company is launching the following to more tightly align its breadth of capabilities and client-centric approach, to bring to market more focused global cybersecurity solutions that encompass people, process and technology.
- Newly launched Global Services and Operations Organization – Optiv has redesigned its services approach centered on client-focused outcomes and is delivering global capabilities to assist clients along their cybersecurity journeys. The company’s breadth of services addresses the full lifecycle of client security needs – with newly launched business lines for Advisory, Integration & Innovation, and CyberOperations - providing global clients with the required focus and scale to execute on full end-to-end cyber risk, cyber digital and cybersecurity projects and programs.
-
Cyber-as-a-Service (CaaS
TM
) Platform
–
designed to ensure organizations benefit from fully-integrated
solutions that scale on-demand with business needs and automatically
adapt to shifting business requirements. This approach enables Optiv
to deliver complex and integrated solutions with an innovative
integrated technology stack focused on client outcomes. Optiv’s new
CaaSTM
offerings can be consumed alone, or combined with
Optiv’s advisory, integration or managed services to harden security
fundamentals across four critical areas of modern business risk:
- Risk management and compliance, including resilience and assurance;
- Cyber digital transformation, including cloud, orchestration, automation and big data;
- Threat management, including protection, detection and response; and
- Identity and data management.
- Global Services Demand (GSD) Organization – Coordinating Partner and Teaming Delivery Model – Optiv created GSD to provide clients with the optimal mix of centralized oversight and buying power, and localized technical resources and expertise. This new engagement model also brings together a seasoned team of regionally-focused senior technical services executives to give clients an important engagement layer atop Optiv’s more than 1,300 deeply skilled and specialized cybersecurity delivery practitioners. These executives serve as global coordinating partners for our clients, acting as a single point of accountability to drive excellence for complex end-to-end cybersecurity services and solutions.
“After more than 40 years since the first virus was launched, the approach to addressing cybersecurity issues has followed the same action and response formula. The challenge is that the world has changed, while the approach to cybersecurity has not kept pace,” said Chad Holmes, chief services and operations officer. “Industries are being completely reinvented – through digital transformation, cloud and data models, Artificial Intelligence (AI), globalization and much more – while cybersecurity gaps expand as symptoms of a historical approach to a new and different business model.”
Holmes continued, “Our new Cyber-as-a-Service consumption model, which we are launching based on client feedback and to meet growing market demand, strongly complements our traditional services model. It enables clients to have a choice in their cybersecurity consumption model, and thereby transform their organizational cybersecurity approach, while benefiting from the same cloud economics that have been used to transform entire industries. This custom developed, innovative and integrated approach provides organizations with increased flexibility and choice in how they procure cybersecurity – from standalone tools to integrated solutions – addressing complex security problems and delivering better alignment to unique business requirements. Optiv is extremely excited to bring to market our new Cyber-as-a-Service, integrated business services and client engagement models, that will increase our ability to provide clients with the right global resources at the right time so that we can truly serve their best interests.”
Please visit our website for more information about our cybersecurity solutions and capabilities.
Follow Optiv
Twitter: www.twitter.com/optiv
LinkedIn:
www.linkedin.com/company/optiv-inc
Facebook:
www.facebook.com/optivinc
YouTube:
https://www.youtube.com/c/OptivInc
Blog:
www.optiv.com/resources/blog
About Optiv Security
Optiv is a global cybersecurity solutions integrator – a “one-stop” trusted partner with a singular focus on cybersecurity. Our end-to-end cybersecurity capabilities span risk management and transformation, cyber digital transformation, threat management, cyber operations, identity and data management, and integration and innovation, helping organizations realize stronger, simpler and more cost-efficient cybersecurity programs that support business requirements and outcomes. At Optiv, we are modernizing cybersecurity to enable clients to innovate their consumption models, integrate infrastructure and technology to maximize value, achieve measurable outcomes, and realize complete solutions and business alignment. For more information about Optiv, please visit us at www.optiv.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190603005657/en/
Contact:
Jason Cook (816) 701-3374 Jason.cook@optiv.com or Brett Ater (913) 304-7683 Brett.ater@optiv.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom